Anti-BCMA CAR-NK Cell therapy - Sichuan Kelun-Biotech Biopharmaceutical

Alternative Names: Anti-BCMA CAR-NK Cells

Latest Information Update: 25 Aug 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sichuan Kelun-Biotech Biopharmaceutical
Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

23 Aug 2021 Xinqiao Hospital of Chongqing in collaboration with Sichuan Kelun-Biotech Biopharmaceutical plans a phase I trial for Multiple Myeloma (In adults, In the elderly, Second-line therapy or greater) in China in September 2021 (NCT05008536)
23 Aug 2021 Preclinical trials in Multiple myeloma in China (Parenteral) before August 2021

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com